Earlier this week, the National Osteoporosis Foundation wrote members of Congress on behalf of more than 200 organizations to express concern over efforts that would allow Medicare to negotiate prices for the Part D drug program.
Specifically, the letter objected to eliminating what is known as the non-interference clause, which prevents the government from negotiating drug prices for Part D. In its note, the organization argued this is a “crucial fixture and protection. … We are very concerned that these changes would have harmful effects on patients and lead to larger access and adherence issues.”
About the Author Reprints
